Argenx is another biotech stock setting up in a textbook breakout pattern. Shares traded up through resistance Monday morning on good volume, but the move was ultimately held back by a nasty overall market. ARGX still held up well, and will likely continue its advance higher.
MRNA has rallied 66% from its bottom set in mid june. Technical indicators suggest a strong turnaround. The P/E ratio and Forward P/E ratio remain in the low single digits. I boosted my position when the price crossed above the 50 day EMA. I will take advantage of any pull-back below the 200 day EMA close or low. Overall, this is still a nice entry point if...
by @newsfile on 2 Aug 2022, 03:15 Breakthrough Discovery: AccuTOX(TM) Effectively Kills Cancer Cells by Directly Eliciting DNA Damage Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development...
Setup was nice. I missed the entry, no FOMO. Must now patiently wait for price to tighten up. There will always be a next train. Risk: 90 bps You don't need to know what's going to happen next to make money ~Mark Douglas Anything can happen ~Mark Douglas
^ Key Words: I'm kicking us off with my pick, which is Mereo Biopharma. Now the stock was actually popping today on an article in "The Times" that says AstraZeneca is putting in a bid for the company. As you can see there, the stock up 73% there. And AstraZeneca also getting a slight boost as well. Now Mereo is a London-based US-listed company that specializes in...
Beautiful capitulation wick, two strong trendline confluence, TD 13 I'm LOVING this chart.
Bavarian Nordic is the only company with an FDA approved Monkey Pox Vaccine Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis...
The market is bleeding, but may be you know this quote: "Bull markets are born on pessimism, grow on skepticism, mature on optimism, and die on euphoria" - Sir John Templeton So the actual question is, where are we right now? I guess "Euphoria" is actually over and we are on our steady way down to realistic valuations. Let's talk facts: As of March 31, 2022,...
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone. Potential indication payments will include asthma, multiple sclerosis, HIV and chemotherapy. In aggregate, this transaction has the ability to generate over $400 million in non-dilutive payments to Statera.
NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation Key patent now granted in major markets including the U.S., Europe, Canada & South Korea Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention deficit hyperactivity disorder (ADHD) &...
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™️ Immunogene Therapy in Combination With Keytruda®️ for the Treatment of Non-Small Cell Lung Cancer Second FDA Fast Track Designation Further Validates the Potential of REQORSA AUSTIN, Texas, January 03, 2022--(BUSINESS WIRE)--Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage...
- $19M mkt cap / 11M float - $28.4M cash eq. - $17.1M Q3 revenue / $7M adjusted EBITDA - Options at $3.27 - Warrants at $3.53 - Enterprise value (as of Sep 30, 2021): $103.8M!! - Canadian Commercial business is focused on Pain, Neurology, Allergy, And Dermatology therapeutics. - 17 Global Distribution Partners across 31 Countries. - Over 100 global patents and...
All, I am already scaled in big here. I am without a doubt this stock will at least double. ***KEEP IN MIND THIS IS AN 8M FLOAT COMPANY 1. Do your own DD you will notice all that has really happened is low float short sellers have just railed the price down 2. This companies price targets are insane not to mention 8M float will make this EXPLODE on any good...
All, Just look at larger timeframes and price targets + last two EPS. I'm going in with 5% stop loss here. No reason not to. Undervalued, float is mediocre nothing great, but absolutely worth a stab here.
Beyond Air has continued a strong uptrend since June. Recently its bin tapering and has shown a symmetrical triangle formation. A Brake out to the upside is likely to continue the uptrend. Watch for a move past the top of the triangle at 11.88 level for conformation and more possible upside. No resistance till 12.50 a high not seen since March 4, 2020
VRPX is another one of the former penny stock darlings of the year. Big breakout mid August put it on everyone's radars now it's about sustaining this higher price level and subsequent valuation. At today's price of around $20.25, the market cap is 3.5x the size it was just a few weeks ago. Thanks to FDA related headlines, VRPX stock skyrocketed. "The FDA has...
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. Excellent bullish divergence on the monthly. Great time for a long trade on this asset that could attempt a retarget in the $ 240 zone.
FULC news catalyst popped the stock into the previous gap and right back to testing this clear resistance level that was previous support. After plotting the fib retracement is looks like the 50 Fib line is an area that might need to set up as the higher support level if there's any hope of FULC sustaining higher levels. We'll have to see what happens next. "The...